Trends in the eradication rates of Helicobacter pylori infection for eleven years

Jai Hoon Yoon, Gwang Ho Baik, Kyoung Min Sohn, Dae Yong Kim, Yeon Soo Kim, Ki Tae Suk, Jin Bong Kim, Dong Joon Kim, Jin Bae Kim, Woon Geon Shin, Hak Yang Kim, Il Hyun Baik, Hyun Joo Jang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

AIM: To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center. METHODS: This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95%CI for the differences in the annual eradication rates. RESULTS: A total of 5746 patients [2333 males (58.8%), 1636 females (41.2%); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5%); duodenal ulcer in 878 (22.1%); gastric and duodenal ulcer in 124 (3.1%), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8%); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5%). The overall eradication rate of the 2 wk standard firstline triple regimen was 86.5%. The annual eradication rates from 2000 to 2010 were 86.7%, 85.4%, 86.5%, 83.3%, 89.9%, 90.5%, 88.4%, 84.5%, 89.1%, 85.8%, and 88.3%, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9%, 82.4%, 85%, 83.9%, 77.3%, 85.7%, 84.4%, 87.3%, 83.3%, 88.9%, and 84% (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7%. There was no significant difference in the eradication rate according to the H. pylori associated diseases. CONCLUSION: This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution.

Original languageEnglish
Pages (from-to)6628-6634
Number of pages7
JournalWorld Journal of Gastroenterology
Volume18
Issue number45
DOIs
StatePublished - 2012 Dec 1

Fingerprint

Helicobacter Infections
Helicobacter pylori
Stomach Ulcer
Duodenal Ulcer
Proton Pump Inhibitors
Clarithromycin
Therapeutics
Atrophic Gastritis
Dyspepsia
Amoxicillin
Metronidazole
Tetracycline
Ulcer
Stomach Neoplasms
Retrospective Studies

Keywords

  • Clarithromycin
  • Eradication
  • Helicobacter pylori
  • Proton pump inhibitor
  • Therapy

Cite this

Yoon, J. H., Baik, G. H., Sohn, K. M., Kim, D. Y., Kim, Y. S., Suk, K. T., ... Jang, H. J. (2012). Trends in the eradication rates of Helicobacter pylori infection for eleven years. World Journal of Gastroenterology, 18(45), 6628-6634. https://doi.org/10.3748/wjg.v18.i45.6628
Yoon, Jai Hoon ; Baik, Gwang Ho ; Sohn, Kyoung Min ; Kim, Dae Yong ; Kim, Yeon Soo ; Suk, Ki Tae ; Kim, Jin Bong ; Kim, Dong Joon ; Kim, Jin Bae ; Shin, Woon Geon ; Kim, Hak Yang ; Baik, Il Hyun ; Jang, Hyun Joo. / Trends in the eradication rates of Helicobacter pylori infection for eleven years. In: World Journal of Gastroenterology. 2012 ; Vol. 18, No. 45. pp. 6628-6634.
@article{3e2e0098dde843fabb81b46dcaa79bb2,
title = "Trends in the eradication rates of Helicobacter pylori infection for eleven years",
abstract = "AIM: To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center. METHODS: This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95{\%}CI for the differences in the annual eradication rates. RESULTS: A total of 5746 patients [2333 males (58.8{\%}), 1636 females (41.2{\%}); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5{\%}); duodenal ulcer in 878 (22.1{\%}); gastric and duodenal ulcer in 124 (3.1{\%}), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8{\%}); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5{\%}). The overall eradication rate of the 2 wk standard firstline triple regimen was 86.5{\%}. The annual eradication rates from 2000 to 2010 were 86.7{\%}, 85.4{\%}, 86.5{\%}, 83.3{\%}, 89.9{\%}, 90.5{\%}, 88.4{\%}, 84.5{\%}, 89.1{\%}, 85.8{\%}, and 88.3{\%}, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9{\%}, 82.4{\%}, 85{\%}, 83.9{\%}, 77.3{\%}, 85.7{\%}, 84.4{\%}, 87.3{\%}, 83.3{\%}, 88.9{\%}, and 84{\%} (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7{\%}. There was no significant difference in the eradication rate according to the H. pylori associated diseases. CONCLUSION: This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution.",
keywords = "Clarithromycin, Eradication, Helicobacter pylori, Proton pump inhibitor, Therapy",
author = "Yoon, {Jai Hoon} and Baik, {Gwang Ho} and Sohn, {Kyoung Min} and Kim, {Dae Yong} and Kim, {Yeon Soo} and Suk, {Ki Tae} and Kim, {Jin Bong} and Kim, {Dong Joon} and Kim, {Jin Bae} and Shin, {Woon Geon} and Kim, {Hak Yang} and Baik, {Il Hyun} and Jang, {Hyun Joo}",
year = "2012",
month = "12",
day = "1",
doi = "10.3748/wjg.v18.i45.6628",
language = "English",
volume = "18",
pages = "6628--6634",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
number = "45",

}

Yoon, JH, Baik, GH, Sohn, KM, Kim, DY, Kim, YS, Suk, KT, Kim, JB, Kim, DJ, Kim, JB, Shin, WG, Kim, HY, Baik, IH & Jang, HJ 2012, 'Trends in the eradication rates of Helicobacter pylori infection for eleven years', World Journal of Gastroenterology, vol. 18, no. 45, pp. 6628-6634. https://doi.org/10.3748/wjg.v18.i45.6628

Trends in the eradication rates of Helicobacter pylori infection for eleven years. / Yoon, Jai Hoon; Baik, Gwang Ho; Sohn, Kyoung Min; Kim, Dae Yong; Kim, Yeon Soo; Suk, Ki Tae; Kim, Jin Bong; Kim, Dong Joon; Kim, Jin Bae; Shin, Woon Geon; Kim, Hak Yang; Baik, Il Hyun; Jang, Hyun Joo.

In: World Journal of Gastroenterology, Vol. 18, No. 45, 01.12.2012, p. 6628-6634.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Trends in the eradication rates of Helicobacter pylori infection for eleven years

AU - Yoon, Jai Hoon

AU - Baik, Gwang Ho

AU - Sohn, Kyoung Min

AU - Kim, Dae Yong

AU - Kim, Yeon Soo

AU - Suk, Ki Tae

AU - Kim, Jin Bong

AU - Kim, Dong Joon

AU - Kim, Jin Bae

AU - Shin, Woon Geon

AU - Kim, Hak Yang

AU - Baik, Il Hyun

AU - Jang, Hyun Joo

PY - 2012/12/1

Y1 - 2012/12/1

N2 - AIM: To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center. METHODS: This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95%CI for the differences in the annual eradication rates. RESULTS: A total of 5746 patients [2333 males (58.8%), 1636 females (41.2%); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5%); duodenal ulcer in 878 (22.1%); gastric and duodenal ulcer in 124 (3.1%), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8%); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5%). The overall eradication rate of the 2 wk standard firstline triple regimen was 86.5%. The annual eradication rates from 2000 to 2010 were 86.7%, 85.4%, 86.5%, 83.3%, 89.9%, 90.5%, 88.4%, 84.5%, 89.1%, 85.8%, and 88.3%, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9%, 82.4%, 85%, 83.9%, 77.3%, 85.7%, 84.4%, 87.3%, 83.3%, 88.9%, and 84% (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7%. There was no significant difference in the eradication rate according to the H. pylori associated diseases. CONCLUSION: This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution.

AB - AIM: To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center. METHODS: This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95%CI for the differences in the annual eradication rates. RESULTS: A total of 5746 patients [2333 males (58.8%), 1636 females (41.2%); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5%); duodenal ulcer in 878 (22.1%); gastric and duodenal ulcer in 124 (3.1%), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8%); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5%). The overall eradication rate of the 2 wk standard firstline triple regimen was 86.5%. The annual eradication rates from 2000 to 2010 were 86.7%, 85.4%, 86.5%, 83.3%, 89.9%, 90.5%, 88.4%, 84.5%, 89.1%, 85.8%, and 88.3%, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9%, 82.4%, 85%, 83.9%, 77.3%, 85.7%, 84.4%, 87.3%, 83.3%, 88.9%, and 84% (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7%. There was no significant difference in the eradication rate according to the H. pylori associated diseases. CONCLUSION: This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution.

KW - Clarithromycin

KW - Eradication

KW - Helicobacter pylori

KW - Proton pump inhibitor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84873904009&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i45.6628

DO - 10.3748/wjg.v18.i45.6628

M3 - Article

C2 - 23236238

AN - SCOPUS:84873904009

VL - 18

SP - 6628

EP - 6634

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 45

ER -